Navigation Links
Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
Date:9/28/2010

induce apoptosis by down-regulating several pivotal oncogenic and tumor survival pathways.

"We are extremely pleased to have completed this financing round, which will enable Tigris to proceed with the development of our two most advanced clinical compounds," stated Edmundo Muniz, MD, PhD, Tigris' President and Chief Executive Officer, adding, "we are honored to have the support of a group of high quality investors, who have demonstrated confidence in our clinical prospects and our management team."

"I am very excited about the opportunity to invest in and lead this financing round for Tigris Pharmaceuticals," said Mr. Flanzraich. "The combination of Tigris' pipeline potential, proven leadership performance, and its vision for the future holds great promise for patients and investors."

The securities were offered to accredited investors in reliance on an exemption from the registration requirements of the Securities Act of 1993 (the "Securities Act").  The offering has not been registered under the Securities Act or any state securities or "blue sky" laws and the shares may not be offered or sold absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

About Tigris Pharmaceuticals, Inc

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology and other human diseases.  Tigris is currently initiating a Phase II trial for AFP-464, a novel anticancer agent in patients with breast cancer and is also conducting a multi-center Phase I dose escalation study for GGTI-2418, another first-in-class agent, at Abramson Cancer Center at The University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center.  

With a management team that has a proven track record in guiding molecules from the early stages of clinical development to successful
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab ... to announce their partnership with Apex Physical Therapy (Apex) is official ... to provide kind, compassionate, and empathetic care to local residents from their combined ...
(Date:9/1/2015)... Diego, CA (PRWEB) , ... September 01, 2015 , ... ... Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. 1, ... Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional hair, ...
(Date:9/1/2015)... New Jersey (PRWEB) , ... September 01, 2015 , ... ... one of the 50 Best Companies for Latinas in the LATINA Style 50 Report ... United States. , For 2015, Horizon BCBSNJ climbs from number 24 ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers ... American Society for Dermatologic Surgery, according to a new survey that also offers ... on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ...
(Date:9/1/2015)... ... 2015 , ... Negative pressure wound therapy (NPWT) entails the ... exudates, fluid, and infectious materials to prepare the wound for healing and closure. ... canisters, etc.) is projected to expand continuously through 2021. , Rising patient and ...
Breaking Medicine News(10 mins):Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... patients following a liver transplant. A new study on risk ... risk factors can be detected before a transplant is done ... ,They found the risk factors - a history of ... with the use of a particular immunosuppressant- increase risk of ...
... you read this sentence, you could be going blind and ... your sight, and there is no cure//. ,January is ... its partner the American Glaucoma Society strongly urges everyone to ... a high risk category, including: ,* African-Americans older ...
... Deprivation - long been associated with an increased risk of ... true – says a recent study// by a University of ... patients, Daniel Vinson, professor of community and family medicine, found ... to be injured. However, patients who reported better sleep quality ...
... issue of the American Chemical Society's journal Nano Letter, ... toxicologists, finds that repetitive movement can speed the uptake ... on the In-Vitro experiments involving animal skin that was ... that repetitive motion can speed the passage of nanoparticles ...
... Manchester University have developed a new software-based approach to ... done by automatically measuring the width of a part ... Horner and Dr Hugh Devlin at the University’s School ... was developed by the Division of Imaging Sciences and ...
... the more likely he or she is to reach ... large new study suggests//. ,The steeper slope ... 14 or younger is of particular concern because their ... of other drinkers,” even when not experiencing stress, according ...
Cached Medicine News:Health News:Risk Factors That Cause NODM After A Liver Transplant 2Health News:Glaucoma: Silently Stealing Sight from Millions 2Health News:A Study Explores the Medical Potentials of Bucky Amino Acids 2Health News:Youngest Drinkers Likelier to Use Alcohol for Stress Relief as Adults 2
ACRYSOF® Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are inten...
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
Multipiece PMMA IOL - Sulcus Fixation....
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
Medicine Products: